vimarsana.com

Page 240 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Foodies Rejoice! Highkey® Continues to Break The Internet with New Drool-Worthy Low-Carb, Sugar-Sucks Products

 known for its #1 best-selling chocolate chip cookie on Amazon with over 30k reviews, is expanding their product line to include even more mouth-watering low-carb and low-sugar treats. A few years ago, I made the resolution cut back on sugar and carbs, and it was really hard, said Aditya (AJ) Patel, Co-Founder of HighKey. I still craved my favorite sugary foods, and I couldn t find healthier alternatives that were tasty and had ingredients I was comfortable with. That s where the idea for HighKey came from. With the help of my co-founder, John Gibb, we ve been able to develop more than 50 delicious products with great macros in two years. I m excited we ll be rolling out 10 of these just in time for the new year so people can have FOMO NO MO and achieve their goals.

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer

Share this article Share this article SAN FRANCISCO and SUZHOU, China, Jan. 11, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and Company ( Lilly ,NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) as second-line therapy for squamous non-small cell lung cancer (sqNSCLC). The application is the third sNDA for TYVYT® (sintilimab injection) in NSCLC. This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3) evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy. Based on the

Open Book Extracts and Case Western Reserve University School of Medicine Announce Research Agreement for Novel Rare Cannabinoid Therapeutics

Open Book Extracts and Case Western Reserve University School of Medicine Announce Research Agreement for Novel Rare Cannabinoid Therapeutics Open Book Extracts and Case Western Reserve University School of Medicine announce research agreement to explore the mechanistic effects of rare cannabinoids on brain cell functions, including CBD, CBG, CBN, CBC, THVC, and CBDV. News provided by Share this article Share this article ROXBORO, N.C., Jan. 12, 2021 /PRNewswire/  Open Book Extracts (OBX), manufacturer and distributor of the industry s most innovative and highest quality cannabinoid ingredients and finished products, and Case Western Reserve University School of Medicine, one of the country s leading private research institutions, announced today they have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions.

Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate

multi-target collaboration launched just over 1 year ago. WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/  Dragonfly Therapeutics ( Dragonfly ), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019 designed to advance a number of Dragonfly s novel NK cell engager-based immunotherapies for autoimmune and oncology indications. AbbVie is committed to delivering improved treatment options to our patients said Tom Hudson, M.D. Senior Vice President, R&D and Chief Scientific Officer at AbbVie.  The collaboration with Dragonfly has been remarkable. Working together, the teams have made rapid progress to develop this first TriNKET in record time.

Pure Barre President Sarah Luna Selected as President of Parent Company Xponential Fitness

Pure Barre President Sarah Luna Selected as President of Parent Company Xponential Fitness New Executive Role to Support Initiatives and Rapid Growth for World s Largest Boutique Fitness Franchisor News provided by Share this article Share this article IRVINE, Calif., Jan. 12, 2021 /PRNewswire/  Xponential Fitness – the largest curator of premium boutique fitness brands including STRIDE – announced today it has appointed Sarah Luna, current President of Pure Barre, to a new executive role as President of Xponential Fitness. In this new position, Luna will drive efficiencies across all eight brands and Xponential departments, lead projects and partnerships for the parent company, and manage efforts with the executive team to achieve their aggressive growth plans. Stepping into Luna s role as President of Pure Barre will be Regan Stokes, the brand s current Senior Vice President of Operations.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.